ClinicalTrials.gg
CompletedNCT04235959Updated Jul 6, 2023Results posted

A Study of Tirzepatide in Chinese Participants With Type 2 Diabetes Mellitus

A Phase 1 interventional study of Tirzepatide and Placebo in Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Completed at 2 sites in China. Open to participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-07-06.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
20 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 — 7 open to participants now, 13 under way, 2 of them phase 3. Tirzepatide · Diabetes Mellitus, Type 2.

Enrollment
42nd of 43
24 · median 160
Started
2020
with 4 others
Phase 1
8 of 43
none open now
Registered
15th of 43
by date
Lead sponsor
31 of 43
Eli Lilly and Company

Among the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, this one is the 42nd largest by enrollment, is one of 5 that started in 2020, is one of 8 in phase 1, and was the 15th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

7 of the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About tirzepatide

Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 20 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The main purpose of this study is to learn more about the safety and side effects of tirzepatide in Chinese participants with type 2 diabetes mellitus. The study will also measure how much tirzepatide gets into the bloodstream and how long it takes the body to remove it. The study will last about six or eight months for each participant.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
20 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have type 2 diabetes mellitus (T2DM) controlled with diet and exercise alone or are stable on a single oral antihyperglycemic medication (OAM), metformin, acarbose, or sulphonylureas only (other types of OAM [dipeptidyl peptidase IV inhibitors, sodium-glucose cotransporter-2 inhibitors, and thiazolidinediones] are not allowed in this study), for at least 3 months
  • Have a body mass greater than or equal to (≥)23 kilograms per square meter (kg/m²), inclusive

Exclusion criteria

Exclusion Criteria:

  • Have type 1 diabetes mellitus
  • Have a history of severe hypoglycemia and/or hypoglycemia unawareness within the 6 months prior to Visit 1
  • Have a history of heart block or PR interval greater than (>)220 milliseconds (msec) or any abnormality in the 12-lead (ECG) at screening that, in the opinion of the investigator, increases the risks associated with participating in the study
  • Have a history or presence of pancreatitis or gastrointestinal (GI) disorder or a GI disease that impacts gastric emptying or could be aggravated by glucagon-like peptide-1 (GLP-1) analogs or dipeptidyl peptidase IV (DPP-IV) inhibitors
  • Have known allergies to tirzepatide, GLP-1 analogs, or related compounds or any components of the formulation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received placebo once weekly (QW) subcutaneously (SC).

    Drug: Placebo

  • Experimental
    Tirzepatide - Cohort 1 (2.5 to 10 Milligram (mg)) and Cohort 2 (2.5 to 15 mg)

    Participants in Cohort 1 received weekly SC doses of tirzepatide with titration regimen starting from 2.5 mg for Weeks 0 through 3 followed by 5 mg for Weeks 4 through 7, 7.5 mg for Weeks 8 through 11, and 10 mg for Weeks 12 through 15. Participants in Cohort 2 received weekly SC doses of tirzepatide with titration regimen starting from 2.5 mg for Weeks 0 through 3 followed by 5 mg for Weeks 4 through 7, 7.5 mg for Weeks 8 through 11, and 10 mg for Weeks 12 through 15, 12.5 mg for Weeks 16 through 19, and 15 mg for Weeks 20 through 23.

    Drug: Tirzepatide

Interventions

  • Administered SC

    Also known as: LY3298176

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration.

    The number of participants with one or more SAEs is assessed as related to the study drug and is summarized cumulatively. A serious adverse event is defined as an event that results in death, initial or prolonged hospitalization, is life-threatening, leads to persistent or significant disability/incapacity, is associated with congenital anomaly/birth defect, or is considered significant by the investigator for any other reason. A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, is reported in the Reported Adverse Events module.

    Time frame: Baseline up to 43 Weeks

Secondary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to 168 Hour Post-dose (AUC [0-168]) of Tirzepatide (Cohort 1)

    PK: AUC \[0-168\] of Tirzepatide.

    Time frame: Week 0 - (Pre-dose, 8, 24, 48, 72, 168 hours post-dose); Week 7 - (Pre-dose, 8, 24, 48, 72, 168 hours post-dose); Week 15 - (Pre-dose, 8, 24, 48, 72, 168 hours post-dose).

  2. PK: AUC [0-168] of Tirzepatide (Cohort 2)

    PK: AUC \[0-168\] of Tirzepatide.

    Time frame: Week 0 - (Pre-dose, 8, 24, 48, 72, 168 hours post-dose); Week 7 - (Pre-dose, 8, 24, 48, 72, 168 hours post-dose); Week 23 - (Pre-dose, 8, 24, 48, 72, 168 hours post-dose).

  3. PK: Maximum Concentration (Cmax) of Tirzepatide (Cohort 1)

    PK: Cmax of Tirzepatide.

    Time frame: Week 0 - (Pre-dose, 8, 24, 48, 72, 168 hours post-dose); Week 7 - (Pre-dose, 8, 24, 48, 72, 168 hours post-dose); Week 15 - (Pre-dose, 8, 24, 48, 72, 168 hours post-dose).

  4. PK: Cmax of Tirzepatide (Cohort 2)

    PK: Cmax of Tirzepatide.

    Time frame: Week 0 - (Pre-dose, 8, 24, 48, 72, 168 hours post-dose); Week 7 - (Pre-dose, 8, 24, 48, 72, 168 hours post-dose); Week 23 - (Pre-dose, 8, 24, 48, 72, 168 hours post-dose).

07

Results

Posted Jul 6, 2023

Participant flow

Participant flow — Overall Study
MilestonePlaceboCohort 1 (2.5 to 10 Milligram (mg) Tirzepatide)Cohort 2 (2.5 to 15 mg Tirzepatide)
Started41010
Received at least one dose of study drug41010
Completed3910
Not completed110
Withdrew: Protocol violation010
Withdrew: Adverse event100

Outcome measures

PrimaryNumber of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration.

The number of participants with one or more SAEs is assessed as related to the study drug and is summarized cumulatively. A serious adverse event is defined as an event that results in death, initial or prolonged hospitalization, is life-threatening, leads to persistent or significant disability/incapacity, is associated with congenital anomaly/birth defect, or is considered significant by the investigator for any other reason. A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, is reported in the Reported Adverse Events module.

Time frame:
Baseline up to 43 Weeks
Reported as:
Number · participants
Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration.
participantsPlaceboCohort 1 (2.5 to 10 Milligram (mg) Tirzepatide)Cohort 2 (2.5 to 15 mg Tirzepatide)
Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration.100
SecondaryPharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to 168 Hour Post-dose (AUC [0-168]) of Tirzepatide (Cohort 1)

PK: AUC \[0-168\] of Tirzepatide.

Time frame:
Week 0 - (Pre-dose, 8, 24, 48, 72, 168 hours post-dose); Week 7 - (Pre-dose, 8, 24, 48, 72, 168 hours post-dose); Week 15 - (Pre-dose, 8, 24, 48, 72, 168 hours post-dose).
Reported as:
Geometric mean · nanogram hour per milliliter (ng*h/mL)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to 168 Hour Post-dose (AUC [0-168]) of Tirzepatide (Cohort 1)
nanogram hour per milliliter (ng*h/mL)Cohort 1: 2.5 to 10 mg Tirzepatide
Week 035100 ± 14
Week 7125000 ± 16
Week 15263000 ± 17
SecondaryPK: AUC [0-168] of Tirzepatide (Cohort 2)

PK: AUC \[0-168\] of Tirzepatide.

Time frame:
Week 0 - (Pre-dose, 8, 24, 48, 72, 168 hours post-dose); Week 7 - (Pre-dose, 8, 24, 48, 72, 168 hours post-dose); Week 23 - (Pre-dose, 8, 24, 48, 72, 168 hours post-dose).
Reported as:
Geometric mean · nanogram hour per milliliter (ng*h/mL)
PK: AUC [0-168] of Tirzepatide (Cohort 2)
nanogram hour per milliliter (ng*h/mL)Cohort 2: 2.5 to 15 mg Tirzepatide
Week 030900 ± 14
Week 7110000 ± 16
Week 23357000 ± 16
SecondaryPK: Maximum Concentration (Cmax) of Tirzepatide (Cohort 1)

PK: Cmax of Tirzepatide.

Time frame:
Week 0 - (Pre-dose, 8, 24, 48, 72, 168 hours post-dose); Week 7 - (Pre-dose, 8, 24, 48, 72, 168 hours post-dose); Week 15 - (Pre-dose, 8, 24, 48, 72, 168 hours post-dose).
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
PK: Maximum Concentration (Cmax) of Tirzepatide (Cohort 1)
nanograms per milliliter (ng/mL)Cohort 1: 2.5 to 10 mg Tirzepatide
Week 0306 ± 28
Week 71030 ± 13
Week 152200 ± 16
SecondaryPK: Cmax of Tirzepatide (Cohort 2)

PK: Cmax of Tirzepatide.

Time frame:
Week 0 - (Pre-dose, 8, 24, 48, 72, 168 hours post-dose); Week 7 - (Pre-dose, 8, 24, 48, 72, 168 hours post-dose); Week 23 - (Pre-dose, 8, 24, 48, 72, 168 hours post-dose).
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
PK: Cmax of Tirzepatide (Cohort 2)
nanograms per milliliter (ng/mL)Cohort 2: 2.5 to 15 mg Tirzepatide
Week 0257 ± 17
Week 7915 ± 18
Week 232930 ± 20

Adverse events

Collected over Up To 43 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/4 (0%)1/4 (25%)4/4 (100%)
Cohort 1 (2.5 to 10 Milligram (mg) Tirzepatide)0/10 (0%)0/10 (0%)10/10 (100%)
Cohort 2 (2.5 to 15 mg Tirzepatide)0/10 (0%)0/10 (0%)10/10 (100%)
Most frequent serious events
Most frequent serious events
EventPlaceboCohort 1 (2.5 to 10 Milligram (mg) Tirzepatide)Cohort 2 (2.5 to 15 mg Tirzepatide)
Acute myocardial infarctionCardiac disorders1/40/100/10
Most frequent other events
Showing 10 of 41
Most frequent other events
EventPlaceboCohort 1 (2.5 to 10 Milligram (mg) Tirzepatide)Cohort 2 (2.5 to 15 mg Tirzepatide)
Decreased appetiteMetabolism and nutrition disorders0/45/108/10
HyperlipidaemiaMetabolism and nutrition disorders3/45/102/10
DiarrhoeaGastrointestinal disorders0/46/104/10
Abdominal distensionGastrointestinal disorders0/42/105/10
Upper respiratory tract infectionInfections and infestations2/40/100/10
NauseaGastrointestinal disorders0/41/104/10
Lipase increasedInvestigations0/41/103/10
Coronary artery diseaseCardiac disorders1/40/100/10
Tooth lossGastrointestinal disorders1/40/100/10
Electrocardiogram qt prolongedInvestigations1/40/100/10

Baseline characteristics

All participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)PlaceboCohort 1 (2.5 to 10 Milligram (mg) Tirzepatide)Cohort 2 (2.5 to 15 mg Tirzepatide)Total
Mean56.5 ± 7.555.8 ± 5.256.8 ± 5.456.3 ± 5.4
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboCohort 1 (2.5 to 10 Milligram (mg) Tirzepatide)Cohort 2 (2.5 to 15 mg Tirzepatide)Total
Female16411
Male34613
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboCohort 1 (2.5 to 10 Milligram (mg) Tirzepatide)Cohort 2 (2.5 to 15 mg Tirzepatide)Total
Hispanic or Latino0000
Not Hispanic or Latino4101024
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboCohort 1 (2.5 to 10 Milligram (mg) Tirzepatide)Cohort 2 (2.5 to 15 mg Tirzepatide)Total
American Indian or Alaska Native0000
Asian4101024
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White0000
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(Participants)PlaceboCohort 1 (2.5 to 10 Milligram (mg) Tirzepatide)Cohort 2 (2.5 to 15 mg Tirzepatide)Total
China4101024
08

Study locations

2 sites
  • West China Hospital Sichuan University
    Cheng Du, Sichuan 610041, China
  • Peking University First Hospital
    Beijing, 100034, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Aug 2021, 9 months.

Results were first posted in Jul 2023, 1 year 10 months after primary completion.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 9 months is above that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2020
First posted
Jan 22, 2020
StartActual
Oct 21, 2020
Primary completionActual
Aug 17, 2021
CompletionActual
Aug 17, 2021
Results first posted
Jul 6, 2023
Last update
Jul 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04235959
Responsible party
Sponsor
First posted
Jan 22, 2020
Start date
Oct 21, 2020
Primary completion
Aug 17, 2021
Completion
Aug 17, 2021
Results posted
Jul 6, 2023
Last update
Jul 6, 2023

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion